Real-World heart failure drug study launches in germany
NCT ID NCT06336330
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This study follows over 800 heart failure patients in Germany who are starting dapagliflozin, a drug recently approved for heart failure. Researchers will track how long patients stay on the drug, any side effects, and changes in symptoms and quality of life. The goal is to understand how the drug works outside of clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Aachen, 52062, Germany
-
Research Site
Alsfeld, 36304, Germany
-
Research Site
Bamberg, 96049, Germany
-
Research Site
Bechhofen, 66894, Germany
-
Research Site
Bergisch Gladbach, 51465, Germany
-
Research Site
Berlin, 12489, Germany
-
Research Site
Berlin, 12555, Germany
-
Research Site
Brilon, 59929, Germany
-
Research Site
Bruchsal, 76646, Germany
-
Research Site
Chemnitz, 09113, Germany
-
Research Site
Dinslaken, 46535, Germany
-
Research Site
Erfurt, 99084, Germany
-
Research Site
Erfurt, 99097, Germany
-
Research Site
Essen, 45128, Germany
-
Research Site
Frankenthal, 67227, Germany
-
Research Site
Gera, 07551, Germany
-
Research Site
Hamburg, 20095, Germany
-
Research Site
Hamburg, 22087, Germany
-
Research Site
Hamburg, 22459, Germany
-
Research Site
Hoppegarten, 15366, Germany
-
Research Site
Kaiserslautern, 67655, Germany
-
Research Site
Kitzingen, 97318, Germany
-
Research Site
Ludwigsburg, 71634, Germany
-
Research Site
Ludwigshafen am Rhein, 67071, Germany
-
Research Site
M Hldorf, 84453, Germany
-
Research Site
Markkleeberg, 4416, Germany
-
Research Site
Meiningen, 98617, Germany
-
Research Site
Münster, 48149, Germany
-
Research Site
Naumburg, 6618, Germany
-
Research Site
Nuremberg, 90402, Germany
-
Research Site
Oschersleben, 39387, Germany
-
Research Site
Papenburg, 26871, Germany
-
Research Site
Pirna, 01796, Germany
-
Research Site
Potsdam, 14471, Germany
-
Research Site
Querfurt, 06268, Germany
-
Research Site
Ratingen, 40882, Germany
-
Research Site
Rostock, 18059, Germany
-
Research Site
Schleswig, 24837, Germany
-
Research Site
Schwandorf in Bayern, 92421, Germany
-
Research Site
Schwäbisch Hall, 74523, Germany
-
Research Site
Siegen, 57072, Germany
-
Research Site
Steinfurt, 48565, Germany
-
Research Site
Stollberg, 09366, Germany
-
Research Site
Straubing, 94315, Germany
-
Research Site
Stuttgart, 70178, Germany
-
Research Site
Ulm, 89073, Germany
-
Research Site
Wermsdorf, 04779, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin
What this could lead to
If successful, this study could show how well dapagliflozin works for heart failure in everyday practice, helping doctors better manage the condition.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by other factors and may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.